Epidemiological features of invasive pneumococcal disease before and after the introduction of pneumococcal conjugate vaccine in Gran Canaria (Canary Islands)

被引:8
|
作者
Artiles, Fernando [1 ]
Horcajada, Iballa [1 ]
Maria Canas, Ana [2 ,3 ]
Alamo, Isabel [1 ]
Bordes, Ana [1 ]
Gonzalez, Agustin [1 ]
Santana, Milagrosa [4 ]
Lafarga, Bernardo [1 ]
机构
[1] Hosp Univ Gran Canaria Dr Negrin, Microbiol Serv, Las Palmas Gran Canaria, Spain
[2] Hosp Univ Gran Canaria Dr Negrin, Unidad Invest, Las Palmas Gran Canaria, Spain
[3] Hosp Clin Roca, Microbiol Serv, San Agustin, Las Palmas, Spain
[4] Hosp Univ Materno Infantil, Serv Pediat, Las Palmas Gran Canaria, Spain
来源
关键词
Streptococcus pneumoniae; Pneumococcal conjugate vaccine; Serotype; Epidemiology; Invasive pneumococcal disease; NONVACCINE SEROTYPES; CHILDREN; SPAIN; REDUCTION; EMERGENCE; CARRIAGE; EFFICACY; IMPACT; RATES;
D O I
10.1016/j.eimc.2008.03.001
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Introduction: The introduction of pneumococcal conjugate vaccine (PCV-7) has modified the epidemiology of invasive pneumococcal disease (IPD). Our aim was to investigate the epidemiological features of IPD before and after implementing the use of PCV-7. Methods: All invasive Streptococcus pneumoniae strains isolated in our hospital from 2000 to 2006 were included. Serotypes were identified and antibiograms were performed in all cases. Data obtained before (2000-2001) and after (2004-2006) authorization of PCV-7 use in Spain were compared. Results: There were 241 cases of IPD. None of the patients with IPD aged 2 years or younger had received PCV-7. PCV-7 coverage in children aged 5 or younger was about 48%. There was a non-significant increase in the incidence of IPD in children (from 53.8 to 57.8 cases/100 000 population), with no change in adults. When IPD incidence was adjusted by the number of blood samples collected, there was a non-significant decrease in both children and adults. Since PCV-7 came on the market, there has been a decrease in vaccine serotypes and an increase in non-vaccine serotypes. The emergent serotypes since that time include 3, 6A, 15, and 19A. Penicillin resistance decreased significantly (p<0.001) from the pre-vaccine period (87.3%) to 2003 (13.8%), and later rose from 2003 through 2006 (41.7%). Erythromycin resistance showed no changes during the study. Conclusions: The incidence of IPD in children aged 2 years and younger in Gran Canaria has not decreased despite the introduction of PCV-7. However, there has been a reduction in the number of cases related to vaccine serotypes and a significant decrease in penicillin resistance. in contrast, non-vaccine serotype IPD cases have increased. Universal vaccination and the use of new polyvalent vaccines may enhance these effects. (C) 2007 Elsevier Espana, S.L. All rights reserved.
引用
收藏
页码:14 / 21
页数:8
相关论文
共 50 条
  • [21] Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine
    Whitney, CG
    Farley, MM
    Hadler, J
    Harrison, LH
    Bennett, NM
    Lynfield, R
    Reingold, A
    Cieslak, PR
    Pilishvili, T
    Jackson, D
    Facklam, RR
    Jorgensen, JH
    Schuchat, A
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (18): : 1737 - 1746
  • [22] Reduction in pediatric invasive pneumococcal disease in the Basque Country and Navarre, Spain, after introduction of the heptavalent pneumococcal conjugate vaccine
    Aristegui, J.
    Bernaola, E.
    Pocheville, I.
    Garcia, C.
    Arranz, L.
    Duran, G.
    Perez, L.
    Bastida, M.
    Canduela, C.
    Aguirre, M. Herranz
    Garrote, E.
    Fletcher, M. A.
    Perez, C.
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2007, 26 (05) : 303 - 310
  • [23] Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease After Introduction Into Routine Pediatric Use
    Baxter, Roger
    Aukes, Laurie
    Pelton, Stephen, I
    Yee, Arnold
    Klein, Nicola P.
    Gruber, William C.
    Scott, Daniel A.
    Center, Kimberly J.
    [J]. JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY, 2021, 10 (02) : 141 - 150
  • [24] Socioeconomic and Racial Disparities of Pediatric Invasive Pneumococcal Disease After the Introduction of the 7-valent Pneumococcal Conjugate Vaccine
    Spicer, Jennifer O.
    Thomas, Stephanie
    Holst, Amy
    Baughman, Wendy
    Farley, Monica M.
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2014, 33 (02) : 158 - 164
  • [25] Decrease in incidence of invasive pneumococcal disease (IPD) in children in northeast Florida after the introduction of the heptavalent conjugate pneumococcal vaccine
    Abuelreish, MA
    Rathore, MH
    [J]. PEDIATRIC RESEARCH, 2003, 53 (04) : 233A - 233A
  • [26] Changing epidemiology of invasive pneumococcal disease in Australian children after introduction of a 7-valent pneumococcal conjugate vaccine
    Williams, Scott R.
    Mernagh, Paul J.
    Lee, Michael H. T.
    Tan, Jonathan T.
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 2011, 194 (03) : 116 - 120
  • [27] Decrease of invasive pneumococcal disease (IPD) in adults after introduction of pneumococcal 13-valent conjugate vaccine in Spain
    Camara, Jordi
    Maria Marimon, Jose
    Cercenado, Emilia
    Larrosa, Nieves
    Quesada, Maria Dolores
    Fontanals, Dionisia
    Cubero, Meritxell
    Perez-Trallero, Emilio
    Fenoll, Asuncion
    Linares, Josefina
    Ardanuy, Carmen
    [J]. PLOS ONE, 2017, 12 (04):
  • [28] Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in Tennessee after introduction of the pneumococcal conjugate vaccine
    Talbot, TR
    Poehling, KA
    Hartert, TV
    Arbogast, PG
    Halasa, NB
    Mitchel, E
    Schaffner, W
    Craig, AS
    Edwards, KM
    Griffin, MR
    [J]. CLINICAL INFECTIOUS DISEASES, 2004, 39 (05) : 641 - 648
  • [29] Reduction in pediatric invasive pneumococcal disease in the Basque Country and Navarre, Spain, after introduction of the heptavalent pneumococcal conjugate vaccine
    J. Aristegui
    E. Bernaola
    I. Pocheville
    C. García
    L. Arranz
    G. Durán
    L. Pérez
    M. Bastida
    C. Canduela
    M. Herranz Aguirre
    E. Garrote
    M. A. Fletcher
    C. Pérez
    [J]. European Journal of Clinical Microbiology & Infectious Diseases, 2007, 26 : 303 - 310